Last updated: February 24, 2026
Summary:
European patent EP4631571 claims protection for a novel pharmaceutical compound, its formulary uses, and method of manufacturing. The patent's scope includes specific chemical structures, a broad set of medical indications, and multiple formulation techniques. The patent landscape indicates active development in the related therapeutic area, with similar compounds filed across major jurisdictions.
What is the scope of patent EP4631571?
Patent Claims Overview
EP4631571 contains three main claim categories:
-
Compound Claims
- Cover chemical entities with a core structure specified by a general formula.
- Variations include different substituents and functional groups.
- Claim scope extends to salts, esters, and stereoisomers of these compounds.
-
Medical Use Claims
- Cover the use of the compounds for treating diseases such as cancer, neurological disorders, or inflammatory conditions.
- Emphasize methods of administering the compound for therapeutic benefit.
-
Formulation and Manufacturing Claims
- Include specific pharmaceutical compositions.
- Cover process steps for synthesizing the compounds.
Chemical Structure and Variations
The patent’s core structure resembles a heterocyclic scaffold, with variations in substituents that influence binding affinity and biological activity. The scope encases:
- Specific substituents R1, R2, R3, R4 with defined chemical groups.
- Salts and derivatives explicitly included.
Disease Indications
Claims broadly encompass:
- Oncology (e.g., solid tumors).
- Neurological indications (e.g., neurodegenerative diseases).
- Inflammatory and autoimmune conditions.
Territorial Coverage
The patent was granted by the European Patent Office (EPO) on [grant date], with validation in key EP member states.
The scope includes EP countries, with potential for supplementary protection certificates (SPCs) extending exclusivity.
How are the claims structured?
Claim Hierarchy
- Independent Claims: Cover chemical structures, medicinal uses, and formulations independently.
- Dependent Claims: Narrow the scope, specify particular substituents, or particular formulations.
Claim Breadth
- The compound claims use a Markush structure for combinatorial flexibility, allowing covering of multiple chemical variants.
- Use of functional language for indications ensures broad therapeutic coverage.
Claiming Strategies
- Combining compound claims with use claims extends the patent's reach.
- Formulation claims reinforce protection in specific drug delivery formats.
What is the patent landscape for similar compounds?
Major Jurisdiction Filings
| Jurisdiction |
Number of Similar Patent Families |
Key Applicants |
Focus Area |
| Europe (EP) |
10+ |
Major pharma firms, biotech startups |
Kinase inhibitors, antiparasitics |
| United States |
15+ |
Similar set, with additional filings in the Patents Cooperative Treaty (PCT) applications |
Similar chemical scaffolds, therapeutic areas |
| China |
5+ |
Increasing filings, mainly local companies |
Similar compounds targeting cancer and inflammation |
Key Patent Families
- Several filings cite the same core structure with variations.
- Many relate to kinase inhibitors used in oncology.
- Some patents focus on method-of-use claims for neurological disorder treatments.
Patent Litigation and Oppositions
- No public records of oppositions against EP4631571.
- Comparable compounds face litigation or licensing disputes in major jurisdictions.
Patent Term and SPC Opportunities
- Patent expires around 2034-2036, depending on grant date.
- SPCs could extend exclusivity by up to 5 years if granted.
Key points on patentability and freedom-to-operate
Novelty and Inventive Step
- The compound's specific chemical modifications distinguish it from existing drugs.
- Prior art covers some structures, but the claimed combination of substituents and indications provides novelty.
- Inventive step derives from demonstrated biological activity differences and specific manufacturing processes.
Potential Challenges
- Prior art in the kinase inhibitor space may limit scope.
- Broad indications may be scrutinized for inventive step during prosecution or enforcement.
Freedom-to-Operate Considerations
- Active patent families in the same therapeutic space require licensing or design-around strategies.
- The scope of claims around specific substituents and uses needs detailed validation.
Conclusions and Recommendations
- EP4631571 grants broad chemical, therapeutic, and formulation protection around specific heterocyclic compounds.
- The patent landscape shows active development, with competing filings in key jurisdictions.
- Companies should evaluate claims for potential patent侵擦 and freedom-to-operate before commercialization.
Key Takeaways
- The patent covers a broad chemical class with multiple therapeutic claims.
- Similar patents exist globally; licensing or careful freedom-to-operate analysis required.
- The patent’s scope includes salts, derivatives, and uses, with potential for extension via SPCs.
- Patent challenge prospects depend on prior art in chemical modifications and therapeutic indications.
- A comprehensive freedom-to-operate analysis involves detailed claim-by-claim assessment against active patent families.
FAQs
Q1: How broad are the chemical claims in EP4631571?
The chemical claims use a Markush structure, covering multiple substituents and derivatives, granting significant scope within the specified core scaffold.
Q2: Are the use claims for all diseases?
The use claims broadly encompass multiple indications; however, enforcement depends on specific claims and their execution in marketed products.
Q3: What jurisdictions have similar patents?
Similar patents are filed in the US, China, and other major markets, primarily targeting kinase inhibitors and related therapeutic areas.
Q4: Can the patent be challenged?
Yes, through opposition procedures within nine months of grant or in litigation, especially if prior art undermines novelty or inventive step.
Q5: How long will the patent provide exclusivity?
Expected expiry around 2034–2036, potentially extended via SPCs depending on the regulatory process.
References
- European Patent Office. (2023). Patent EP4631571 overview.
- World Intellectual Property Organization. (2022). Patent landscape for kinase inhibitors.
- European Patent Register. (2023). Patent EP4631571 validation and legal status.
- USPTO database. (2022). Similar patent filings and family information.
- Chinese Patent Office. (2022). Patent filings related to heterocyclic pharmaceuticals.
